How to Withdraw a Drug: FDA’s Final Decision on Avastin
This article was originally published in RPM Report
Executive Summary
The “streamlined withdrawal” process for Avastin in metastatic breast cancer gave Genentech an extra 11 months to prepare for the transition to off-label status. It also gave FDA time to make preparations of its own.